Citation Impact
Citing Papers
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
2014
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer
2017
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers
2016
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
2016
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
2016
Breast cancer
2019 Standout
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
2015
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
2019 StandoutNobel
Head and neck squamous cell carcinoma
2020 Standout
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2017
Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
2015
A view on drug resistance in cancer
2019 StandoutNature
Breast cancer
2016 Standout
Hepatocellular carcinoma
2016 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
2014
Cellular senescence in aging and age-related disease: from mechanisms to therapy
2015 Standout
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Hepatocellular carcinoma
2021 Standout
Cancer-associated cachexia
2018 Standout
Synthetic lethality as an engine for cancer drug target discovery
2019
Pyroptosis: mechanisms and diseases
2021 Standout
Chemotherapy and the war on cancer
2005 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
2016
The antitumor toxin CD437 is a direct inhibitor of DNA polymerase α
2016
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex
2019
Common pitfalls in preclinical cancer target validation
2017 StandoutNobel
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer
2015
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
2015
Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma
2018
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
The molecular landscape of head and neck cancer
2018 Standout
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
The PI3K Pathway in Human Disease
2017 Standout
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative
2016
Hepatocellular Carcinoma
2019 Standout
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.
1964
Improving Prospects for Targeting RAS
2015
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
2015
Genetic Landscape of Human Papillomavirus–Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors
2015
Breast Cancer Treatment
2019 Standout
Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease
1970 Standout
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
2016
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Targeting CDK4 and CDK6: From Discovery to Therapy
2015
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
2016
Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment
2015
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
2018
Works of Anu Thummala being referenced
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
2020
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
2014 Standout
Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)
2014